Stock Analysis, Dividends, Split History

MRTX / Mirati Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price59.30
Volume1,541,900.00
Market Cap ($M)1,949.60
Enterprise Value ($M)1,843.64
Book Value ($M)246.34
Book Value / Share7.61
Price / Book7.91
NCAV ($M)244.75
NCAV / Share7.56
Price / NCAV7.97
Share Statistics
Common Stock Shares Outstanding 28,622,886
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 28,940,161
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.49
Return on Assets (ROA)-1.11
Return on Equity (ROE)-1.46
Balance Sheet (mrq) ($M)
Assets265.19
Liabilities18.84
Quick Ration/a
Current Ratio14.54
Income Statement (mra) ($M)
Revenues0.00
License And Services Revenue0.00
Operating Income-71.53
Net Income-70.43
Earnings Per Share Diluted-70,430,000.00
Earnings Per Share Basic-2.78
Cash Flow Statement (mra) ($M)
Cash From Operations-64.71
Cash from Investing-8.65
Cash from Financing-8.65
Identifiers and Descriptors
CUSIP60468T105
Central Index Key (CIK)1576263
Related CUSIPS
60468T955 60468T905

Split History

Stock splits are used by Mirati Therapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
MRTX: Mirati Therapeutics Analysis and Research Report

2018-06-26 - Asif

Overview Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer. The company's precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who are most likely to benefit from targeted drug treatment. In immuno-oncology, Mirati Therapeutics is advancing clinical programs where the ability of its product candidates to improve the immune environment of tumor cells may enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. The company's preclinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. The company approach each of its discovery and development programs with a singular focus: to translate its deep understanding of the molecular drivers of canc...

Related News Stories

Small Caps Are Rising, Biotechs Can't Be Far Behind

2018-09-05 seekingalpha
While much attention is being riveted on the S&P 500's new all-time high eclipsing the January one, small caps accomplished that in May. (142-9)

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-08-24 zacks
Launched on 07/19/2012, the Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Blend segment of the US equity market. (6-0)

Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment

2018-08-07 seekingalpha
Mirati is a gift that keeps on giving, as the company logged astronomical profits for shareholders. (11-0)

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-08-01 zacks
The Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) was launched on 07/19/2012, and is a passively managed exchange traded fund designed to offer broad exposure to the Small Cap Blend segment of the US equity market. (2-0)

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-07-09 zacks
Launched on 07/19/2012, the Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Blend segment of the US equity market. (2-0)

Mirati Therapeutics: How Much Higher Can This 'Rocket' Go?

2018-06-21 seekingalpha
The shares of small oncology concern Mirati Therapeutics have shot past $50 recently, less than a year after we first recommended the equity at $5. (73-0)

Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

2018-06-20 biospace
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight. (310-6)

A Short Case For A Longer Term!

2018-06-20 seekingalpha
Most investors should favor a longer-term time frame as the markets again record new highs after recovering from the first quarter pullback. (311-10)

Institutional Top Ideas: Great Point Partners

2018-06-19 seekingalpha
Great Point Partners has high returns of late and a significantly concentrated portfolio while avoiding extreme overweighting we´ve seen with certain other funds. (161-2)

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

2018-06-15 zacks
Looking for broad exposure to the Small Cap Blend segment of the US equity market? You should consider the PowerShares DWA SmallCap Momentum Portfolio (DWAS - Free Report) , a passively managed exchange traded fund launched on 07/19/2012. (74-0)

CUSIP: 60468T105